These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 29544728

  • 21. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT, Reisner C, Pearle J, DePetrillo P, Maes A, Martin UJ.
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [Abstract] [Full Text] [Related]

  • 22. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.
    Respir Res; 2017 Jan 06; 18(1):8. PubMed ID: 28061907
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 06; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 24. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM, Siler TM, Arora S, Darken P, Rose E, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2018 Jun 06; 13():1483-1494. PubMed ID: 29773947
    [Abstract] [Full Text] [Related]

  • 25. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.
    Aurivillius M, Bednarczyk A, Kokot M, Madriaga J, Mei J, Collison K, Surujbally R, Archbell J, Joshi V, Gillen M.
    Pulm Pharmacol Ther; 2023 Dec 06; 83():102245. PubMed ID: 37607661
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C, Pearle J, Kerwin EM, Rose ES, Darken P.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 06; 13():1965-1977. PubMed ID: 29950826
    [Abstract] [Full Text] [Related]

  • 27. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
    Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P.
    Respir Med; 2019 Dec 06; 158():59-66. PubMed ID: 31605923
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
    Taylor G, Warren S, Dwivedi S, Sommerville M, Mello L, Orevillo C, Maes A, Martin UJ, Usmani OS.
    Eur J Pharm Sci; 2018 Jan 01; 111():450-457. PubMed ID: 29055732
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.
    Respir Med; 2016 Nov 01; 120():16-24. PubMed ID: 27817811
    [Abstract] [Full Text] [Related]

  • 34. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C.
    Respir Res; 2020 May 25; 21(1):128. PubMed ID: 32450869
    [Abstract] [Full Text] [Related]

  • 35. Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.
    Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2021 May 25; 16():179-189. PubMed ID: 33542624
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 May 25; 15():43-56. PubMed ID: 32021143
    [Abstract] [Full Text] [Related]

  • 39. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
    Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ.
    Int J Chron Obstruct Pulmon Dis; 2018 May 25; 13():2969-2984. PubMed ID: 30310273
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.